Resources from the same session
Which checkpoint inhibitor, in which biomarker sub-group and when: What is approved, what is coming and what are the trials telling us
Presenter: Sibylle Loibl
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Slides
Webcast
PARP inhibition in early breast cancer: What have we learned and how can we move forward?
Presenter: Andrew Tutt
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Slides
Webcast
PARP inhibitor combination strategies in early breast cancer: Rationale and results to date
Presenter: Kevin Punie
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
Resources:
Webcast